Covera Health Launches ‘Protect Her™’ – A Breakthrough AI Solution to Advance Early Detection in Women’s Health
New AI-powered platform leverages routine imaging to identify hidden health risks for women as they age, improving quality of life...
Heart Attack
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic...
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr...
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD)...
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides...
Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent
RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone...
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL...
Tren-Max (Crazybulk) safe and legal steroid alternative to Trenbolone Acetate, Dosages Cycles Benefits and Guide to Buying Tren Ace, Tren Steroid For Sale!
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- “Tren-Max is the safe and legal steroid alternative to Trenbolone Acetate" Our...
US Remote Patient Monitoring Market worth US$29.13 billion by 2030 with 12.8% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., March 20, 2025 /PRNewswire/ -- The global US Remote Patient Monitoring Market, valued at US$14.15 billion in...
PeopleOne Health Launches Free, Targeted Programs to Combat Chronic Disease
New pathways for cardiovascular health, weight management, and diabetes improve well-being while lowering healthcare costsPITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE)...
Nuralogix Announces Its Next-Generation Anura® MagicMirror™: Advanced Health Monitoring Now with 4G Connectivity
Next-gen smart mirror integrates AI-powered health monitoring with seamless 4G connectivity for enhanced telehealth, retail, and wellness applications TORONTO, March...
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain...
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed...
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious...
Marius Pharmaceuticals Helps Drive FDA’s Landmark Testosterone Label Update, Removing Black Box Warning
RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, is pleased to announce that the U.S. Food and Drug...
MyOme Announces Launch of CAD iPRS and Beginning Enrollment in the COMPASS-CAD Prospective Trial
MyOme Launches Integrated Risk Tool for Coronary Artery Disease MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a...
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) — Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events...
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first...
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended...